Equities analysts expect Nevro Corp (NYSE:NVRO) to announce sales of $93.65 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Nevro’s earnings, with the lowest sales estimate coming in at $90.70 million and the highest estimate coming in at $97.60 million. Nevro reported sales of $95.63 million in the same quarter last year, which indicates a negative year-over-year growth rate of 2.1%. The business is scheduled to announce its next earnings report after the market closes on Wednesday, November 6th.

According to Zacks, analysts expect that Nevro will report full-year sales of $374.22 million for the current year, with estimates ranging from $370.80 million to $381.82 million. For the next year, analysts expect that the business will report sales of $411.83 million, with estimates ranging from $405.60 million to $417.60 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Nevro.

Nevro (NYSE:NVRO) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.02). The company had revenue of $93.60 million during the quarter, compared to analyst estimates of $88.40 million. Nevro had a negative return on equity of 41.07% and a negative net margin of 24.51%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.35) earnings per share.

Several research firms have issued reports on NVRO. Northland Securities set a $65.00 price target on shares of Nevro and gave the stock a “hold” rating in a research report on Friday, August 9th. Canaccord Genuity raised their price objective on Nevro from $50.00 to $59.00 and gave the company a “hold” rating in a research note on Friday, August 9th. Bank of America raised their price objective on Nevro from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Friday, August 9th. ValuEngine cut Nevro from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, JMP Securities raised their price objective on Nevro from $70.00 to $90.00 and gave the company a “market outperform” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $69.27.

NYSE NVRO traded down $0.41 during midday trading on Thursday, hitting $85.00. The company had a trading volume of 237,994 shares, compared to its average volume of 331,157. The company has a quick ratio of 4.66, a current ratio of 6.05 and a debt-to-equity ratio of 0.89. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of -51.83 and a beta of 0.21. The firm has a fifty day simple moving average of $85.06 and a two-hundred day simple moving average of $70.18. Nevro has a fifty-two week low of $34.75 and a fifty-two week high of $91.60.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVRO. Quantamental Technologies LLC bought a new stake in Nevro in the 2nd quarter valued at about $75,000. Atria Investments LLC bought a new position in shares of Nevro in the 2nd quarter worth $267,000. Prudential Financial Inc. bought a new position in shares of Nevro in the 2nd quarter worth $202,000. Aperio Group LLC bought a new position in shares of Nevro in the 2nd quarter worth $227,000. Finally, Marshall Wace North America L.P. raised its position in shares of Nevro by 27.3% in the 1st quarter. Marshall Wace North America L.P. now owns 4,390 shares of the medical equipment provider’s stock worth $276,000 after acquiring an additional 941 shares in the last quarter.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Article: Municipal Bonds

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.